![Hugh Jackson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Hugh Jackson
Directeur/Membre du Conseil chez Actimed Therapeutics Ltd.
Postes actifs de Hugh Jackson
Sociétés | Poste | Début | Fin |
---|---|---|---|
Actimed Therapeutics Ltd.
![]() Actimed Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education. | Directeur/Membre du Conseil | - | - |
Directeur Financier/CFO | - | 19/10/2023 |
Historique de carrière de Hugh Jackson
Statistiques
Internationale
Royaume-Uni | 2 |
Opérationnelle
Director/Board Member | 1 |
Director of Finance/CFO | 1 |
Sectorielle
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Actimed Therapeutics Ltd.
![]() Actimed Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education. | Commercial Services |
- Bourse
- Insiders
- Hugh Jackson
- Expérience